Patheon Doubles Biologics Capacity at St. Louis Facility

Published on: 

Thermo Fisher Scientific invests $50 Million to expand biologics drug development and manufacturing capabilities in St. Louis, MO.

Thermo Fisher Scientific announced in a press statement on April 23, 2018 that is investing $50 million in the Patheon Biologics Center of Excellence (COE) for Biological Commercial Manufacturing in St. Louis, MO, to expand the company’s biologic drug substance capabilities for clinical and commercial supply.

The project includes a 64,000-sq.-ft. expansion to the existing manufacturing building #2 and will feature Thermo Fisher bioproduction bioreactors, consumables, and factory automation. The capacity expansion will double the site’s manufacturing capacity and will give Thermo Fisher the second largest base of single-use bioproduction capacity at a contract development and manufacturing organization in the world, the company reports.

The investment will also allow for further expansion in the future and will add approximately 80 new technical jobs. The company reports the site will be operational in 2019.


The Patheon Biologics Network of four sites has standardized on a 2000L, single-use platform as for new drug development through to commercialization. The St Louis site provides process development, clinical cGMP manufacturing, and commercial manufacturing using fed batch and perfusion processes.

Source: Patheon, part of Thermo Fisher Scientific